Physician profile
Robert J Dean
NPI 1609859859
$5,641.92
in general payments reported to CMS, 2019-2025
35 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $590 · 2021: $738 · 2022: $882 · 2023: $870 · 2024: $844 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,745 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,745.04 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,072.86 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $1,019.11 | 2020-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $780.15 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $294.84 | 2019-2025 | |
| Mylan Specialty L.P. | $255.99 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $248.66 | 2019-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $146.70 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $139.83 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Amgen INC. | $137.49 | 2022-2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $125.59 | 2021-2025 | |
| Grifols USA, LLC | $119.56 | 2022-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $109.99 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $109.60 | 2021-2024 | Glassia |
| Ani Pharmaceuticals, INC. | $107.30 | 2023-2025 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $97.15 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $80.76 | 2021-2025 | Tyvaso, Tyvaso |
| Pfizer INC. | $80.04 | 2022-2023 | |
| Baxter Healthcare | $76.99 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Janssen Pharmaceuticals, INC | $66.88 | 2019-2021 | |
| Electromed, INC. | $65.46 | 2019-2025 | Smartvest |
| Harmony Biosciences LLC | $62.96 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.60 | 2019 | |
| Genentech USA, INC. | $54.13 | 2019-2022 | |
| Verona Pharma, INC. | $47.38 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $46.94 | 2020 | |
| Mallinckrodt Enterprises LLC | $45.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.44 | 2019-2025 | |
| Resmed Corp | $32.25 | 2022-2023 | |
| Olympus America INC. | $30.53 | 2022-2024 | Single-Use Flexible Video Bronchoscope |
| Medtronic, INC. | $17.78 | 2023 | Illumisite |
| Philips North America LLC | $16.50 | 2024 | (Ak6) Vest Therapy |
| Vifor Pharma, INC. | $16.25 | 2024 | Zemaira |
| Axsome Therapeutics, INC. | $15.88 | 2025 | Sunosi |
| Pulmonx Corporation | $14.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.